Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) EBIT Margin (2021 - 2025)

Lyra Therapeutics has reported EBIT Margin over the past 5 years, most recently at 101685.71% for Q4 2025.

  • Quarterly results put EBIT Margin at 101685.71% for Q4 2025, down 9622734.0% from a year ago — trailing twelve months through Dec 2025 was 7794.47% (down 151364.0% YoY), and the annual figure for FY2025 was 7794.47%, down 151364.0%.
  • EBIT Margin for Q4 2025 was 101685.71% at Lyra Therapeutics, down from 24948.0% in the prior quarter.
  • Over the last five years, EBIT Margin for LYRA hit a ceiling of 2548.08% in Q1 2022 and a floor of 137772.73% in Q4 2022.
  • Median EBIT Margin over the past 5 years was 4931.81% (2025), compared with a mean of 23017.71%.
  • Biggest five-year swings in EBIT Margin: tumbled -13274025bps in 2022 and later soared 12648711bps in 2023.
  • Lyra Therapeutics' EBIT Margin stood at 5032.47% in 2021, then tumbled by -2638bps to 137772.73% in 2022, then surged by 92bps to 11285.62% in 2023, then surged by 52bps to 5458.37% in 2024, then crashed by -1763bps to 101685.71% in 2025.
  • The last three reported values for EBIT Margin were 101685.71% (Q4 2025), 24948.0% (Q3 2025), and 4822.95% (Q2 2025) per Business Quant data.